Prognostic value of heterogeneous ribonucleoprotein A1 expression and inflammatory indicators for patients with surgically resected hepatocellular carcinoma: Perspectives from a high occurrence area of hepatocellular carcinoma in China Erratum in /10.3892/ol.2018.9580

Ke,Ruisheng; Lv,Lizhi; Li,Jiayan; Zhang,Xiaojin; Yang,Fang; Zhang,Kun; Jiang,Yi

doi:10.3892/ol.2018.9079

Prognostic value of heterogeneous ribonucleoprotein A1 expression and inflammatory indicators for patients with surgically resected hepatocellular carcinoma: Perspectives from a high occurrence area of hepatocellular carcinoma in China

Erratum in: /10.3892/ol.2018.9580

Authors:
- Ruisheng Ke
- Lizhi Lv
- Jiayan Li
- Xiaojin Zhang
- Fang Yang
- Kun Zhang
- Yi Jiang
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China, Department of Surgery, Fuzhou Hospital of Traditional Chinese Medicine, Fuzhou, Fujian 350025, P.R. China, Department of Hepatobiliary Surgery, Fuzhou General Hospital, Fuzhou, Fujian 350025, P.R. China, Department of Hepatobiliary Surgery, The Fuzhou Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China
Published online on: July 4, 2018 https://doi.org/10.3892/ol.2018.9079
Pages: 3746-3756
Copyright: © Ke et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Heterogeneous ribonucleoproteinA1 (hnRNPA1) is a documented tumor biomarker known to be aberrantly expressed in a number of types of human cancer. However, to the best of our knowledge, its prognostic value for surgically resected HCC (RHCC) in the high incidence areas of China has not been described; the association between hnRNPA1 expression, pre‑operative neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) is also not understood. In the present study, hnRNPA1 expression was retrospectively measured in two independent cohorts of patients with hepatocellular carcinoma (HCC) who underwent surgery to remove the primary cancer at one center in Fujian, an area with a high incidence of HCC in China. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR), western blotting and immunohistochemistry (IHC) were used to quantify hnRNPA1 expression in RHCC tissues. The survival curves were plotted using the Kaplan‑Meier method, and the prognostic significance of hnRNPA1, NLR and PLR was analyzed using the log‑rank test. The relevant prognostic factors were identified by multivariate Cox regression analysis. RT‑qPCR and western blotting revealed that hnRNPA1 was upregulated in HCC tissues (P<0.001), and particularly overexpressed in tumor tissues of patients with recurrent HCC (P<0.001) (cohort 1; 54 patients). Differential hnRNPA1 expression was measured in 426HCC tissues with IHC; 259 exhibited high hnRNPA1 expression and 167 exhibited low expression. High hnRNPA1 expression was significantly associated with Tumor‑Node‑Metastasis stage (P=0.024), tumor size (P=0.027), vascular invasion (P<0.001), Edmonson grade (P<0.001), pre‑operative serum α‑fetoprotein (AFP) (P<0.001), NLR (P<0.001) and PLR (P<0.001). In addition, multivariate Cox regression analysis confirmed that high hnRNPA1 expression was associated with relapse‑free survival (RFS; HR, 0.685; 95% CI, 0.506‑0.928; P=0.015) and overall survival (OS; HR, 0.629; 95% CI, 0.454‑0.871; P=0.005). Multivariate analysis confirmed that higher pre‑operative serum AFP had an unfavorable impact on RFS (HR, 1.350; 95% CI, 1.006‑1.811; P=0.045) and OS (HR=1.564; 95% CI, 1.151‑2.126; P=0.004), while higher pre‑operative NLR had an unfavorable impact on OS (HR, 1.758; 95% CI, 1.161‑2.661; P=0.008) (cohort 2;426 patients). The expression of hnRNPA1 was also positively correlated with NLR (Spearman's correlation; r=0.122, P=0.012) and PLR (Spearman's correlation; r=0.140, P=0.004). In conclusion, high hnRNPA1 expression was revealed as prognostic for poor survival in patients with RHCC, and detection of hnRNPA1 protein in tumor tissues demonstrated potential in estimating survival for patients with RHCC in areas with high incidence rates. Furthermore, the combination of high hnRNPA1 expression and pre‑operative serum AFP levels (>400 µg) proved to be a good diagnostic and prognostic biomarker for this specific population of patients. Finally, a correlation may also exist between hnRNPA1 expression and other markers of systemic inflammation.

View Figures

View References

1	Yan X and Qiu Y: Impact of current staging systems on treatment strategy for HBV-related hepatocellular carcinoma. Cancer Lett. 379:220–224. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Zhang S, Zhao P, Zeng H and Zou X: Report of cancer incidence and mortality in China, 2010. Ann Transl Med. 2:612014.PubMed/NCBI
3	Olsen SK, Brown RS and Siegel AB: Hepatocellular carcinoma: Review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol. 3:55–66. 2010. View Article : Google Scholar : PubMed/NCBI
4	Wang CH, Wey KC, Mo LR, Chang KK, Lin RC and Kuo JJ: Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev. 16:3595–3604. 2015. View Article : Google Scholar : PubMed/NCBI
5	Jonas S, Al-Abadi H, Benckert C, Thelen A, Hippler-Benscheid M, Saribeyoglu K, Radtke B, Pratschke J and Neuhaus P: Prognostic significance of the DNA-index in liver transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg. 250:1008–1013. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kim E, Goren A and Ast G: Insights into the connection between cancer and alternative splicing. Trends Genet. 24:7–10. 2008. View Article : Google Scholar : PubMed/NCBI
7	Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, et al: Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 365:1384–1395. 2011. View Article : Google Scholar : PubMed/NCBI
8	Han SP, Tang YH and Smith R: Functional diversity of the hnRNPs: Past, present and perspectives. Biochem J. 430:379–392. 2010. View Article : Google Scholar : PubMed/NCBI
9	LaBranche H, Dupuis S, Ben-David Y, Bani MR, Wellinger RJ and Chabot B: Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase. Nat Genet. 19:199–202. 1998. View Article : Google Scholar : PubMed/NCBI
10	Cammas A, Lacroix-Triki M, Pierredon S, Le Bras M, Iacovoni JS, Teulade-Fichou MP, Favre G, Roché H, Filleron T, Millevoi S and Vagner S: hnRNP A1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression. Oncotarget. 7:16793–16805. 2016. View Article : Google Scholar : PubMed/NCBI
11	David CJ, Chen M, Assanah M, Canoll P and Manley JL: HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 463:364–368. 2010. View Article : Google Scholar : PubMed/NCBI
12	Ma YL, Peng JY, Zhang P, Huang L, Liu WJ, Shen TY, Chen HQ, Zhou YK, Zhang M, Chu ZX and Qin HL: Heterogeneous nuclear ribonucleoprotein A1 is identified as a potential biomarker for colorectal cancer based on differential proteomics technology. J Proteome Res. 8:4525–4535. 2009. View Article : Google Scholar : PubMed/NCBI
13	Golan-Gerstl R, Cohen M, Shilo A, Suh SS, Bakàcs A, Coppola L and Karni R: Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res. 71:4464–4472. 2011. View Article : Google Scholar : PubMed/NCBI
14	Zhou ZJ, Dai Z, Zhou SL, Fu XT, Zhao YM, Shi YH, Zhou J and Fan J: Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma. Int J Cancer. 132:1080–1089. 2013. View Article : Google Scholar : PubMed/NCBI
15	Tazzyman S, Barry ST, Ashton S, Wood P, Blakey D, Lewis CE and Murdoch C: Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int J Cancer. 129:847–858. 2011. View Article : Google Scholar : PubMed/NCBI
16	Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, Rusch VW, Travis WD and Adusumilli PS: Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res. 17:5247–5256. 2011. View Article : Google Scholar : PubMed/NCBI
17	Wei K, Wang M, Zhang W, Mu H and Song TQ: Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Med Oncol. 31:9692014. View Article : Google Scholar : PubMed/NCBI
18	Cao Y, Ke R, Wang S, Zhu X, Chen J, Huang C, Jiang Y and Lv L: DNA topoisomerase IIalpha and Ki67 are prognostic factors in patients with hepatocellular carcinoma. Oncol Lett. 13:4109–4116. 2017. View Article : Google Scholar : PubMed/NCBI
19	Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, et al: Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer. 120:2650–2655. 2007. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Wu X, Liu H, Liu J, Haley KN, Treadway JA, Larson JP, Ge N, Peale F and Bruchez MP: Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol. 21:41–46. 2003. View Article : Google Scholar : PubMed/NCBI
22	Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Fushiya N, Koike K, Nishino H and Tajiri H: Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer. 107:988–993. 2012. View Article : Google Scholar : PubMed/NCBI
23	Dong L, Bai K, Cao Y, Huang Q, Lv L and Jiang Y: Prognostic value of pre-operative platelet to lymphocyte ratio in patients with resected primary hepatocellular carcinoma. Clin Lab. 62:2191–2196. 2016. View Article : Google Scholar : PubMed/NCBI
24	Jean-Philippe J, Paz S and Caputi M: hnRNP A1: The Swiss army knife of gene expression. Int J Mol Sci. 14:18999–19024. 2013. View Article : Google Scholar : PubMed/NCBI
25	Zhang S, Wei JS, Li SQ, Badgett TC, Song YK, Agarwal S, Coarfa C, Tolman C, Hurd L, Liao H, et al: MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Lett. 371:214–224. 2016. View Article : Google Scholar : PubMed/NCBI
26	Luan W, Wang Y, Chen X, Shi Y, Wang J, Zhang J, Qian J, Li R, Tao T, Wei W, et al: PKM2 promotes glucose metabolism and cell growth in gliomas through a mechanism involving a let-7a/c-Myc/hnRNPA1 feedback loop. Oncotarget. 6:13006–13018. 2015. View Article : Google Scholar : PubMed/NCBI
27	Ford LP, Wright WE and Shay JW: A model for heterogeneous nuclear ribonucleoproteins in telomere and telomerase regulation. Oncogene. 21:580–583. 2002. View Article : Google Scholar : PubMed/NCBI
28	Chettouh H, Fartoux L, Aoudjehane L, Wendum D, Clapéron A, Chrétien Y, Rey C, Scatton O, Soubrane O, Conti F, et al: Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors. Cancer Res. 73:3974–3986. 2013. View Article : Google Scholar : PubMed/NCBI
29	Liu X, Zhou Y, Lou Y and Zhong H: Knockdown of HNRNPA1 inhibits lung adenocarcinoma cell proliferation through cell cycle arrest at G0/G1 phase. Gene. 576:791–797. 2016. View Article : Google Scholar : PubMed/NCBI
30	Zhen L, Shijie N and Shuijun Z: Tumor PHD2 expression is correlated with clinical features and prognosis of patients with HCC receiving liver resection. Medicine. 93:e1792014. View Article : Google Scholar : PubMed/NCBI
31	Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, et al: Barcelona clinic liver cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: A multicentre, cohort study. Lancet Oncol. 12:654–662. 2011. View Article : Google Scholar : PubMed/NCBI
32	Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI
33	Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K and Zigeuner R: Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 108:901–907. 2013. View Article : Google Scholar : PubMed/NCBI
34	de Visser KE, Eichten A and Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 6:24–37. 2006. View Article : Google Scholar : PubMed/NCBI
35	Aliustaoglu M, Bilici A, Ustaalioglu BB, Konya V, Gucun M, Seker M and Gumus M: The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol. 27:1060–1065. 2010. View Article : Google Scholar : PubMed/NCBI
36	Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP and Prasad KR: Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 32:1757–1762. 2008. View Article : Google Scholar : PubMed/NCBI
37	Song W, Wang K, Zhong FP, Fan YW, Peng L and Zou SB: Clinicopathological and prognostic significance of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma. Oncotarget. 7:81830–81838. 2016. View Article : Google Scholar : PubMed/NCBI
38	Qi X, Li J, Deng H, Li H, Su C and Guo X: Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Oncotarget. 7:45283–45301. 2016. View Article : Google Scholar : PubMed/NCBI